Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011

Ironwood Pharmaceuticals to Host Fourth Quarter 2010 Investor Update Call


  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. st-fourth-quarter-2010-investor-update-call.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--[ Ironwood Pharmaceuticals, Inc. ] (NASDAQ: IRWD) today announced it will host its fourth quarter 2010 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, March 3, 2011. Individuals interested in participating in the call should dial (888) 206-4836 (U.S. and Canada) or (913) 312-0679 (international) using conference ID number 9353790. To access the webcast, please visit the Investors section of Ironwooda™s website at [ www.ironwoodpharma.com ] at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting March 3, 2011, at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on March 17, 2011. To listen to the replay, dial (888) 203-1112 (U.S. and Canada) or (719) 457-0820 (international) using conference ID number 9353790. The archived webcast will be available on Ironwooda™s website for 14 days beginning approximately one hour after the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwooda™s GCaC agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBSaC) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.


Publication Contributing Sources